相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Letter
Medicine, General & Internal
Heba N. Altarawneh et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Cell Biology
Yueh-Ming Loo et al.
Summary: AZD7442, a combination of two monoclonal antibodies, has the potential to prevent and treat COVID-19 by neutralizing the SARS-CoV-2 virus. It has shown encouraging results in preventing infection and accelerating virus clearance in animal models. The ongoing phase 1 study has also demonstrated its ability to provide long-lasting protection in healthy participants. This research is significant in providing additional options for COVID-19 prevention and treatment.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Letter
Urology & Nephrology
Dominique Bertrand et al.
KIDNEY INTERNATIONAL
(2022)
Editorial Material
Medicine, General & Internal
Helene Vaillant-Roussel et al.
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE
(2022)
Article
Medicine, General & Internal
Myron J. Levin et al.
Summary: A single dose of AZD7442 showed efficacy in preventing Covid-19 without evident safety concerns. The study suggests that AZD7442 may provide potential protection for individuals who have an inadequate response to vaccination or an increased risk of exposure.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Ori Magen et al.
Summary: The use of a fourth dose of BNT162b2 vaccine in Israel starting on January 3, 2022, has shown significant reductions in infection rate, symptomatic infection, hospitalization, and Covid-19-related deaths by February 18.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Immunology
Ayman Al Jurdi et al.
Summary: This study investigated the immune responses of kidney transplant recipients (KTRs) after SARS-CoV-2 mRNA vaccination and found that there was no significant alloimmune response. Approximately half of the recipients who developed anti-wild-type spike antibodies showed neutralizing responses against the Delta variant, and there was no association between anti-viral humoral and cellular responses.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Yair Goldberg et al.
Summary: This study used data from the Israeli Ministry of Health database to compare the rate of infection with the time since immunity-confering events. The results showed that the protection against reinfection decreased over time for individuals who had previously been infected or vaccinated, but it was still higher than the protection conferred after the same time had elapsed since the second dose of vaccine among those who were previously uninfected. A single dose of vaccine after infection reinforced protection against reinfection.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Surgery
Sophie Caillard et al.
Summary: Transplant recipients had a higher COVID-19-related mortality compared to nontransplant hospitalized patients but did not differ significantly in the rate of severe disease. Factors associated with severe COVID-19 included age, cardiovascular disease, dyspnea, fever, lymphopenia, and CRP.
AMERICAN JOURNAL OF TRANSPLANTATION
(2021)
Article
Immunology
Megan M. Sheehan et al.
Summary: The study found that prior infection in patients with COVID-19 provided a high level of protection against reinfection and symptomatic disease, with this protection increasing over time. This suggests that viral shedding or ongoing immune response may persist beyond 90 days, and may not necessarily represent true reinfection.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Medicine, General & Internal
Christian Holm Hansen et al.
Summary: The study investigated the protection against SARS-CoV-2 reinfection, with results showing an 80.5% protection rate for individuals previously infected. Even in the population aged 65 years and older, the protection rate against reinfection reached 47.1%, with no significant differences observed by gender or time since infection.
Article
Medicine, General & Internal
Victoria Jane Hall et al.
Summary: This study investigated whether antibodies against SARS-CoV-2 were associated with a decreased risk of symptomatic and asymptomatic reinfection. It found that individuals with a previous history of SARS-CoV-2 infection had an 84% lower risk of reinfection, with a median protective effect lasting for 7 months following primary infection.
